BTW
MYGN icon

Boston Trust Walden’s Myriad Genetics MYGN Stock Holding History

Boston Trust Walden’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-701,984
Closed -$14.7M – 327
2013
Q4 		$14.7M Sell
701,984
-579,986
-45% -$14.7M 0.21% 158
2013
Q3 		$30.1M Sell
1,281,970
-18,977
-1% -$539K 0.46% 101
2013
Q2 		$35M Buy
+1,300,947
New +$37.7M 0.56% 75

Other funds holding MYGN

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $24B AUM 39.59% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Boston Trust Walden's MYGN Position: Q1 2014 in Review

Boston Trust Walden sold out of Myriad Genetics (MYGN) in Q1 2014, closing a stake of 701,984 shares — an estimated $14.7M sold.

Boston Trust Walden first reported a position in MYGN in Q2 2013 and held it in 3 quarters. The position peaked at $35M in Q2 2013. 281 funds tracked by Wall St. Rank hold MYGN as of Q1 2014.

  • Boston Trust Walden reported no remaining Myriad Genetics position as of Q1 2014 after selling out during the quarter.
  • Boston Trust Walden sold 701,984 Myriad Genetics shares in Q1 2014, an estimated $14.7M.
  • Boston Trust Walden first reported a position in Myriad Genetics in Q2 2013 and held it in 3 quarters.
  • Boston Trust Walden's Myriad Genetics position peaked at $35M in Q2 2013.
  • 281 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2014.

Based on Boston Trust Walden's 13F filing for Q1 2014, filed 11 Apr 2014.